Acute Intermittent Porphyria Global Market Report 2025

Description

Acute intermittent porphyria (AIP) is a rare genetic disorder affecting the production of heme, an essential component of hemoglobin in the blood. It is characterized by intermittent episodes of severe abdominal pain, gastrointestinal issues, and neurological symptoms such as muscle weakness, seizures, and mental disturbances including anxiety, confusion, or hallucinations.

Diagnosing acute intermittent porphyria typically involves urine tests, blood tests, serum tests, DNA tests, and others. Urine tests analyze a sample to detect elevated levels of porphyrins or their precursors, which indicate AIP. Treatment options include prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others. These diagnostic and treatment approaches are utilized by hospitals, clinics, ambulatory surgical centers, and research centers.

The acute intermittent porphyria market research report is one of a series of new reports from The Business Research Company that provides acute intermittent porphyria market statistics, including acute intermittent porphyria industry global market size, regional shares, competitors with a acute intermittent porphyria market share, detailed acute intermittent porphyria market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. This acute intermittent porphyria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.37 $ billion in 2024 to $4.66 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising healthcare expenditure, growth in biopharmaceuticals market, rising prevalence of genetic disorders, expansion of telemedicine services, and growing focus on early detection.

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.96 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, growing patient advocacy, and expansion of genetic testing services. Major trends in the forecast period include advancements in diagnostic techniques, development of novel therapeutic options, investment in research and development, collaborations between pharma companies, and technological innovations in treatment.

The increasing prevalence of metabolic disorders is expected to drive growth in the acute intermittent porphyria (AIP) market. Metabolic disorders are conditions caused by abnormal chemical reactions in the body that disrupt normal metabolism. Factors such as genetic predispositions, lifestyle choices, environmental influences, and heightened awareness and diagnosis contribute to the rise in these disorders. This increase is prompting the pharmaceutical industry to invest in treatments for rare and genetic conditions, including acute intermittent porphyria. For example, the Cleveland Clinic reported in December 2023 that inherited metabolic disorders affect approximately 1 in 1,000 to 2,500 births globally, highlighting the growing need for targeted treatments like those for AIP.

Leading companies in the AIP market are focusing on developing advanced products, such as management tablets, to improve patient care. These tablets are designed to manage or prevent symptoms and acute attacks associated with AIP. In October 2023, Alembic Pharmaceuticals Ltd., based in India, received US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, available in various doses (10 mg, 25 mg, 50 mg, 100 mg, and 200 mg). These tablets are used to manage symptoms of psychotic disorders, control nausea and vomiting, and provide relief from other conditions, including acute intermittent porphyria.

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, collaborated with Recordati Rare Diseases. This partnership aims to raise awareness about porphyria and enhance public support and understanding of AIP. Recordati Rare Diseases, an Italy-based, involved in the treatment of acute intermittent porphyria.

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

North America was the largest region in the acute intermittent porphyria market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute intermittent porphyria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Intermittent Porphyria Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute intermittent porphyria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute intermittent porphyria ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute intermittent porphyria market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Diagnosis: Urine Test; Blood Test; Serum Test; DNA Test; Other Diagnosis
2) By Treatment: Prophylactic Hematin Infusions; Gonadotropin-Releasing Hormone Analogues; Other Treatments
3) By End-Users: Hospitals And Clinics; Ambulatory Surgical Centers; Research Centers
Subsegments:
1) By Urine Test: Urine Porphobilinogen (PBG) Test; Urine Aminolevulinic Acid (ALA) Test; Urine Color Change Test
2) By Blood Test: Plasma Porphyrin Levels Test; Blood Aminolevulinic Acid (ALA) Test; Complete Blood Count (CBC) Test
3) By Serum Test: Serum Porphyrin Levels Test; Liver Function Test (LFT); Serum ALA and PBG Enzyme Test
4) By DNA Test: Genetic Mutation Testing; Gene Sequencing Test
5) By Other Diagnosis: Stool Test for Porphyrins; Imaging Tests (CT/MRI Scans for Complications); Enzyme Activity Assays.
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r31568

1. Executive Summary

2. Acute Intermittent Porphyria Market Characteristics

3. Acute Intermittent Porphyria Market Trends And Strategies

4. Acute Intermittent Porphyria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Intermittent Porphyria Growth Analysis And Strategic Analysis Framework

5.1. Global Acute Intermittent Porphyria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Acute Intermittent Porphyria Market Growth Rate Analysis
5.4. Global Acute Intermittent Porphyria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Acute Intermittent Porphyria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Acute Intermittent Porphyria Total Addressable Market (TAM)

6. Acute Intermittent Porphyria Market Segmentation

6.1. Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urine Test
Blood Test
Serum Test
DNA Test
Other Diagnosis
6.2. Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prophylactic Hematin Infusions
Gonadotropin-Releasing Hormone Analogues
Other Treatments
6.3. Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals and Clinics
Ambulatory Surgical Centers
Research Centers
6.4. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urine Porphobilinogen (PBG) Test
Urine Aminolevulinic Acid (ALA) Test
Urine Color Change Test
6.5. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma Porphyrin Levels Test
Blood Aminolevulinic Acid (ALA) Test
Complete Blood Count (CBC) Test
6.6. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Serum Porphyrin Levels Test
Liver Function Test (LFT)
Serum ALA and PBG Enzyme Test
6.7. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genetic Mutation Testing
Gene Sequencing Test
6.8. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stool Test for Porphyrins
Imaging Tests (CT/MRI Scans for Complications)
Enzyme Activity Assays

7. Acute Intermittent Porphyria Market Regional And Country Analysis

7.1. Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Intermittent Porphyria Market

8.1. Asia-Pacific Acute Intermittent Porphyria Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Intermittent Porphyria Market

9.1. China Acute Intermittent Porphyria Market Overview
9.2. China Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Intermittent Porphyria Market

10.1. India Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Intermittent Porphyria Market

11.1. Japan Acute Intermittent Porphyria Market Overview
11.2. Japan Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Intermittent Porphyria Market

12.1. Australia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Intermittent Porphyria Market

13.1. Indonesia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Intermittent Porphyria Market

14.1. South Korea Acute Intermittent Porphyria Market Overview
14.2. South Korea Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Intermittent Porphyria Market

15.1. Western Europe Acute Intermittent Porphyria Market Overview
15.2. Western Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Intermittent Porphyria Market

16.1. UK Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Intermittent Porphyria Market

17.1. Germany Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Intermittent Porphyria Market

18.1. France Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Intermittent Porphyria Market

19.1. Italy Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Intermittent Porphyria Market

20.1. Spain Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Intermittent Porphyria Market

21.1. Eastern Europe Acute Intermittent Porphyria Market Overview
21.2. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Intermittent Porphyria Market

22.1. Russia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Intermittent Porphyria Market

23.1. North America Acute Intermittent Porphyria Market Overview
23.2. North America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Intermittent Porphyria Market

24.1. USA Acute Intermittent Porphyria Market Overview
24.2. USA Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Intermittent Porphyria Market

25.1. Canada Acute Intermittent Porphyria Market Overview
25.2. Canada Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Intermittent Porphyria Market

26.1. South America Acute Intermittent Porphyria Market Overview
26.2. South America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Intermittent Porphyria Market

27.1. Brazil Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Intermittent Porphyria Market

28.1. Middle East Acute Intermittent Porphyria Market Overview
28.2. Middle East Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Intermittent Porphyria Market

29.1. Africa Acute Intermittent Porphyria Market Overview
29.2. Africa Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Intermittent Porphyria Market Competitive Landscape And Company Profiles

30.1. Acute Intermittent Porphyria Market Competitive Landscape
30.2. Acute Intermittent Porphyria Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Intermittent Porphyria Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. AstraZeneca Plc
31.3. Novartis AG
31.4. GlaxoSmithKline Plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Gilead Sciences Inc.
31.8. Amgen Inc.
31.9. Novo Nordisk A/S
31.10. Regeneron Pharmaceuticals Inc.
31.11. Daiichi Sankyo Company Limited
31.12. Vertex Pharmaceuticals Inc.
31.13. Eisai Co. Ltd.
31.14. Octapharma AG
31.15. BioMarin Pharmaceutical Inc.

32. Global Acute Intermittent Porphyria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Intermittent Porphyria Market

34. Recent Developments In The Acute Intermittent Porphyria Market

35. Acute Intermittent Porphyria Market High Potential Countries, Segments and Strategies

35.1 Acute Intermittent Porphyria Market In 2029 - Countries Offering Most New Opportunities
35.2 Acute Intermittent Porphyria Market In 2029 - Segments Offering Most New Opportunities
35.3 Acute Intermittent Porphyria Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer